ChiCTR2600122273 版本V1.0 版本创建时间2026/04/10 17:03:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600122273 

最近更新日期:

Date of Last Refreshed on:

2026-04-10 17:03:49 

注册时间:

Date of Registration:

2026-04-10 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

口腔癌前损害无创智能化风险预测模型的多中心临床应用研究

Public title:

A Multicenter Clinical Study on the Application of a Non-invasive Intelligent Risk Prediction Model for OPMDs

注册题目简写:

English Acronym:

研究课题的正式科学名称:

口腔癌前损害无创智能化风险预测模型的多中心临床应用研究

Scientific title:

A Multicenter Clinical Study on the Application of a Non-invasive Intelligent Risk Prediction Model for OPMDs

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王悦琪 

研究负责人:

夏娟 

Applicant:

Yueqi Wang 

Study leader:

Juan Xia 

申请注册联系人电话:

Applicant telephone:

+86 20 8387 0405

研究负责人电话:

Study leader's telephone:

+86 20 8387 0405

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1776764732@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xiajuan@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区中山二路74号

研究负责人通讯地址:

广东省广州市越秀区陵园西路56号

Applicant address:

No. 74, Zhongshan 2nd Road, Yuexiu District, Guangzhou City, Guangdong Province

Study leader's address:

No. 56, Lingyuan West Road, Yuexiu District, Guangzhou City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学

Applicant's institution:

Sun Yat-sen University

研究负责人所在单位:

中山大学附属口腔医院

Affiliation of the Leader:

Hospital of Stomatology, SunYat-sen University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KQEC-2025-075-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属口腔医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Hospital of Stomatology, Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-24 00:00:00

伦理委员会联系人:

向媛媛

Contact Name of the ethic committee:

Yuanyuan Xiang

伦理委员会联系地址:

广东省广州市越秀区陵园西路56号

Contact Address of the ethic committee:

No. 56, Lingyuan West Road, Yuexiu District, Guangzhou City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 83844247

伦理委员会联系人邮箱:

Contact email of the ethic committee:

463563264@qq.com

研究实施负责(组长)单位:

中山大学附属口腔医院

Primary sponsor:

Hospital of Stomatology, SunYat-sen University

研究实施负责(组长)单位地址:

广东省广州市越秀区陵园西路56号

Primary sponsor's address:

No. 56, Lingyuan West Road, Yuexiu District, Guangzhou City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属口腔医院

具体地址:

广东省广州市越秀区陵园西路56号

Institution
hospital:

Hospital of Stomatology, SunYat-sen University

Address:

No. 56, Lingyuan West Road, Yuexiu District, Guangzhou City, Guangdong Province

经费或物资来源:

广东省口腔疾病临床医学研究中心 “临床研究专项”

Source(s) of funding:

Guangdong Provincial Clinical Medical Research Center for Oral Diseases

Target disease:

Potential malignant lesion of the oral mucosa

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

主要研究目的: 建立风险预测模型:比较多种建模方式并开发一个基于无创技术的口腔潜在恶性疾病风险预测的最优模型,旨在通过临床数据和无创检测结果,准确评估患者的癌变风险。这一模型将 为临床医生提供决策支持,帮助其制定个性化的监测和治疗方案。 次要研究目的: 1.评估不同检测方法的临床相关性:研究不同无创检测方法(如 TCT、DNA 倍体分析、基因甲基化检测)与口腔潜在恶性病变病理分级之间的关系,明确各检测方法在早期诊断中的有 效性和适用性。 2. 寻找 OPMDs 癌变潜在靶点:筛选口腔黏膜癌变的潜在靶点,以便在临床实践中更精准地应用模型,提升早期诊断的准确性。  

Objectives of Study:

Main research objective: Establish a risk prediction model: Compare various modeling approaches and develop an optimal model for predicting the risk of oral potential malignant diseases based on non-invasive techniques, aiming to accurately assess the cancer risk of patients through clinical data and non-invasive test results. This model will provide decision support for clinicians, helping them to formulate personalized monitoring and treatment plans. Secondary research objectives: 1. Evaluate the clinical relevance of different detection methods: Study the relationship between different non-invasive detection methods (such as TCT, DNA ploidy analysis, gene methylation detection) and the pathological grading of oral potential malignant lesions, and clarify the effectiveness and applicability of each detection method in early diagnosis. 2. Identify potential targets for cancer transformation in OPMDs: Screen potential targets for oral mucosal cancer transformation, so as to apply the model more precisely in clinical practice and improve the accuracy of early diagnosis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.临床和病理诊断为符合无异常增生,伴黏膜上皮轻、中、重度异常增生的口腔红斑、口腔白斑病、口腔扁平苔藓、口腔黏膜下纤维性变等口腔潜在恶性病变,以及鳞状细胞癌患者;
2.未经激素、激光、放射线或化学药物治疗;
3.能签署知情同意书;

Inclusion criteria

1.Clinical and pathological diagnosis of oral erythema, oral leukoplakia, oral lichen planus, oral submucosal fibrosis, and other potential malignant lesions in the oral cavity with mild, moderate, and severe abnormal hyperplasia of mucosal epithelium, as well as patients with squamous cell carcinoma;
2.Not treated with hormones, lasers, radiation, or chemical drugs;
3.People who can sign informed consent forms;

排除标准:

1.无法满足随访;
2.数据大量缺失或不全;

Exclusion criteria:

1.Unable to meet follow-up requirements;
2.Massive missing or incomplete data;

研究实施时间:

Study execute time:

From 2025-06-24 00:00:00 To 2028-02-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-07-10 00:00:00 To 2028-02-29 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

本研究以组织病理学检查结果作为金标准。所有入组病例均接受病损部位活检,由病理医师依据 WHO 2017 口腔上皮异常增生分级标准进行判读,用作评价无创检测及联合模型诊断效能的参考标准。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Histopathological examination of biopsy specimens will serve as the gold/reference standard. All enrolled cases will undergo biopsy, and pathological grading will be determined according to the WHO 2017 criteria for oral epithelial dysplasia.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

指标试验为基于口腔脱落细胞的无创检测,包括液基薄层细胞学、DNA 倍体分析及 DNA 甲基化检测,并进一步构建三模态联合模型用于癌变风险判断。

Index test:

The index tests are noninvasive oral exfoliative cell-based assessments, including liquid-based cytology (LBC), DNA ploidy analysis, and DNA methylation testing (ZNF582 and SHOX2), and a trimodal combined model will be further developed for cancer risk assessment.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

目标人群为临床怀疑 OPMDs 且需行病理活检评估的口腔黏膜病损患者。

例数:

Sample size:

122

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

The target population comprises patients with oral mucosal lesions who are clinically suspected of having OPMDs and require histopathological biopsy evaluation.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

本研究不单独设置容易混淆的疾病人群。

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

No separate population with conditions likely to be confused with the target condition is specifically defined in this study.

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

中山大学附属口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Hospital of Stomatology, SunYat-sen University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

中山市口腔医院 

单位级别:

三级 

Institution
hospital:

Hospital of Stomatology, Zhongshan City

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

佛山市口腔医院 

单位级别:

三级甲等 

Institution
hospital:

Foshan Stomatology Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

预测模型的一致性与校准表现

指标类型:

次要指标

Outcome:

The consistency and calibration performance of the prediction model

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

模型的区分能力

指标类型:

主要指标

Outcome:

The model's ability to distinguish

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

口腔脱落细胞样本

组织:

Sample Name:

Oral exfoliative cell sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究数据预计于研究结束后6个月内共享至ResMan临床试验公共管理平台(http://www.medresman.org.cn/login.aspx),项目名称为:口腔癌前损害无创智能化风险预测模型的多中心临床应用研究

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data from this study are expected to be shared on the ResMan Public Clinical Trial Management Platform(http://www.medresman.org.cn/login.aspx) within 6 months after study completion, under the project title: " A Multicenter Clinical Application Study of a Noninvasive Risk Prediction Model for OPMDs"

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用统一病例报告表收集临床资料、病理结果及相关检测结果。研究数据由专人录入、核对并进行去标识化管理,数据库设访问权限并定期备份,统一整理和统计分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standardized case report form will be used to collect clinical data, pathological results, and relevant testing results. Study data will be entered, checked, and managed in a de-identified manner by designated staff. The database will be access-controlled and regularly backed up, and the data will be cleaned and analyzed.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-10 17:03:49